MYC-driven U2SURP regulates alternative splicing of SAT1 to promote triple-negative breast cancer progression

Deng, Ling; Liao, Li; Zhang, Yinling; Hu, Shu‐Yuan; Yang, Shao‐Ying; Ma, Xiao-Yan; Huang, Min-Ying; Zhang, Fang-Lin; Li, Da‐Qiang

doi:10.1016/j.canlet.2023.216124

Cited by 10 publications

(4 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased expression of EIF3D can enhance the translation of U2SURP and play an important role in promoting triple-negative breast cancer (TNBC) cell tumorigenesis and metastasis in vivo and in vitro . 18 The mutation type C > T occurred on the “chr3:101859127-101859628” in LumB subtype, which increased the activity of the enhancer but downregulated the expression of its downstream target genes NFKBIZ, ZPLD1, ZBTB11, SENP7, CEP97, and NXPE3 ( Figure 3 E; Table S1 ). Target gene NFKBIZ is an independent prognostic feature of breast cancer.…”

Section: Resultsmentioning

confidence: 99%

Identification of somatic mutation-driven enhancers and their clinical utility in breast cancer

Zhao,

Feng,

Lei

et al. 2024

iScience

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Identification of somatic mutation-driven enhancers and their clinical utility in breast cancer

Zhao,

Feng,

Lei

et al. 2024

iScience

View full text Add to dashboard Cite

“…In the KEGG pathway analyses, eight coding RNAs of the cell cycle and seven RNAs involved in cellular senescence were identified as probably the key‐coding RNAs involved in significantly heightening the malignant potential of vimentin‐positive IBC‐NSTs. Among these, since MYC, CDK6 , and E2F3 which were significantly upregulated are involved in both the cell cycle and cellular senescence pathways, these coding RNAs are probably especially closely involved in heightening the malignant potential of vimentin‐positive IBC‐NSTs 37–39 . Thirteen GO terms consisted of many important coding RNAs that could play very important roles in heightening the malignant potential of vimentin‐positive IBC‐NSTs; among these, the 12 coding RNAs that were significantly upregulated in three or more GO terms may be especially important coding RNAs (Table 4).…”

Section: Discussionmentioning

confidence: 99%

“…Among these, since MYC, CDK6, and E2F3 which were significantly upregulated are involved in both the cell cycle and cellular senescence pathways, these coding RNAs are probably especially closely involved in heightening the malignant potential of vimentinpositive IBC-NSTs. [37][38][39] Thirteen GO terms consisted of many important coding RNAs that could play very important roles in heightening the malignant potential of vimentin-positive IBC-NSTs; among these, the 12 coding RNAs that were significantly upregulated in three or more GO terms may be especially important coding RNAs (Table 4). [40][41][42][43][44][45][46][47][48][49][50][51] This study clearly demonstrated a higher Ki67 labeling index of vimentin-positive IBC-NSTs than that of vimentin-negative IBC-NSTs; since all of the 12 coding RNAs play important roles in…”

Section: Mitotic Cytokinesismentioning

confidence: 99%

Vimentin‐positive invasive breast carcinoma of no special type: A breast carcinoma with lethal biological characteristics

Ichinose,

Hasebe,

Hirasaki

et al. 2023

Pathology International

View full text Add to dashboard Cite

Vimentin is a stable mesenchymal immunohistochemical marker and is widely recognized as a major marker of mesenchymal tumors. The purpose of the present study was to investigate if the vimentin expression status might serve as a significant predictor of outcomes in patients with invasive breast carcinoma of no special type (IBC‐NST) and to investigate, by comprehensive RNA sequencing analyses, the mechanisms involved in the heightened malignant potential of vimentin‐positive IBC‐NSTs. This study, conducted using the data of 855 patients with IBC‐NST, clearly identified vimentin expression status as a very important independent biological parameter for accurately predicting the outcomes in patients with IBC‐NST. RNA sequence analyses clearly demonstrated significant upregulation of coding RNAs known to be closely associated with cell proliferation or cellular senescence, and significant downregulation of coding RNAs known to be closely associated with transmembrane transport in vimentin‐positive IBC‐NSTs. We conclude that vimentin‐positive IBC‐NSTs show heightened malignant biological characteristics, possibly attributable to the upregulation of RNAs closely associated with proliferative activity and cellular senescence, and downregulation of RNAs closely associated with transmembrane transport in IBC‐NSTs.

show abstract

“…SRSF1 directly binds to the PTMT1 exon 3, leading to the production of the long isoform and resulting in carcinogenic effects through the AKT/C-MYC axis. 231 Deng et al 232 studied MYC-regulated ASEs in TNBC and found that MYC enhances U2SURP translation, a poorly defined member of the SRSF family, through eukaryotic translation initiation factor 3 subunit D (eIF3D)-dependent mechanism, leading to an accumulation of U2SURP in TNBC and promoting SAT1 AS by removing intron 3. This increases SAT1 mRNA stability and expression level, enhancing the carcinogenic potential and malignant phenotype of TNBC cells.…”

Section: Breast Cancer (Brca)mentioning

confidence: 99%

Alternative splicing and related RNA binding proteins in human health and disease

Tao,

Zhang,

Wang

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Alternative splicing (AS) serves as a pivotal mechanism in transcriptional regulation, engendering transcript diversity, and modifications in protein structure and functionality. Across varying tissues, developmental stages, or under specific conditions, AS gives rise to distinct splice isoforms. This implies that these isoforms possess unique temporal and spatial roles, thereby associating AS with standard biological activities and diseases. Among these, AS-related RNA-binding proteins (RBPs) play an instrumental role in regulating alternative splicing events. Under physiological conditions, the diversity of proteins mediated by AS influences the structure, function, interaction, and localization of proteins, thereby participating in the differentiation and development of an array of tissues and organs. Under pathological conditions, alterations in AS are linked with various diseases, particularly cancer. These changes can lead to modifications in gene splicing patterns, culminating in changes or loss of protein functionality. For instance, in cancer, abnormalities in AS and RBPs may result in aberrant expression of cancer-associated genes, thereby promoting the onset and progression of tumors. AS and RBPs are also associated with numerous neurodegenerative diseases and autoimmune diseases. Consequently, the study of AS across different tissues holds significant value. This review provides a detailed account of the recent advancements in the study of alternative splicing and AS-related RNA-binding proteins in tissue development and diseases, which aids in deepening the understanding of gene expression complexity and offers new insights and methodologies for precision medicine.

show abstract

MYC-driven U2SURP regulates alternative splicing of SAT1 to promote triple-negative breast cancer progression

Cited by 10 publications

References 63 publications

Identification of somatic mutation-driven enhancers and their clinical utility in breast cancer

Identification of somatic mutation-driven enhancers and their clinical utility in breast cancer

Vimentin‐positive invasive breast carcinoma of no special type: A breast carcinoma with lethal biological characteristics

Alternative splicing and related RNA binding proteins in human health and disease

Contact Info

Product

Resources

About